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GBV-C/HGV and HIV-1 Coinfection
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An interesting interaction pattern has been found between HIV-1 and GBV-C/HGV, resulting
in protection against progression to AIDS. The mechanisms involved in this interaction remain to
be clarified. We examined the current knowledge concerning this coinfection and developed
hypotheses to explain its effects. A better understanding of this interaction could result in new
concepts, which may lead to new strategies to control HIV-1 replication and progression to AIDS.
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Patients infected with the human immunodeficiency
virus (HIV) are often co-infected with other pathogens,
especially hepatitis viruses [1]. Coinfection with hepatitis
B virus (HBV) or hepatitis C virus (HCV) appears to
increase the mortality rate among HIV-infected patients
[2], in the same way as the course of HCV infection is
accelerated in patients who are coinfected with HIV,
when compared with immunocompetent individuals
[3,4]. A new virus related to hepatitis C virus was
identified in 1995; it was initially thought to be another
hepatitis agent [5,6]. It has been described as either
GB virus C (GBV-C) [5] or hepatitis G virus (HGV)
[6]. GBV-C and HGV are closely related, with more
than 95 percent sequence homology [7]. The name
GBV-C has been more widely used, since it appears
that this virus is not a causative agent of hepatitis [7,8].
GB virus C (GBV-C), an RNA virus in the
Flaviviridae family, has a genome very similar to that of
hepatitis C virus (HCV), coding for structural and
nonstructural proteins. There is a nontranslated region
(NTR) at 5’ that can serve as an internal ribosomal
entry site to direct translation of the uncapped message
(genome) RNA [9]. GVB-C appears to encode two
structural glycoproteins, which constitute the virus
envelope proteins E1 and E2. However, the precise
composition of the nucleocapsid has yet to be defined.
To date, five genotypes of HGV have been described,
with 12 percent divergence between them [10,11].
Genotype 1 is predominant in West Africa, genotype
2 in Europe and the USA, genotype 3 in Asia,
genotype 4 in Southeast Asia and genotype 5 in South
Africa [12]. In Brazil, two reports have described
the genotype distribution. Oliveira et al. evaluated 17
GVB-C-infected blood donors using RFLP, of which
10 (59%) were infected by genotype 2b, four infected
by genotype 2a (24%), and three by genotype 1
(18%) [13]. Nishiya et al. screened over 1,000
healthy subjects, and analyzed 24 GVB-C-infected
patients, using RT-PCR followed by genome
sequencing; they found 12 subjects infected by
genotype 2a (50%), 10 by genotype 2b (42%), and
two by genotype 1 (8.3%) [14].
Although many people are infected with this virus
throughout the world, no clear association with a known
disease state has been demonstrated. GBV-C is
transmitted predominantly through parenteral routes,
with a high seroprevalence among intravenous illicit
drug users, although sexual transmission has also been
reported [15].
Based on the very low density of the virus particles,
it appears that GBV-C associates with lipids in human
serum, and like HCV, it may use the low density
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lipoprotein receptor for virus binding and entry into
target cells [16]. Virus derived from an infectious
molecular clone can replicate in CD
4
+ cells in peripheral
blood mononuclear cell (PBMC) cultures [17].
GBV-C clearance is common in immunocompetent
subjects, occurring in approximately 60 to 75% of
GBV-C-infected persons, along with the development
of antibodies against the envelope glycoprotein E2 [18].
GBV-C infection has not been associated with any
known disease and does not appear to represent a
substantial threat to public health. For this reason, the
Food and Drug Administration (FDA) has not
recommended screening blood donors for GBV-C
RNA, although this persistent infection is common,
present in approximately 1.8% of American donors and
more than 35% of the HIV-infected subjects [19]. In
Brazil, the prevalence of HGV in blood donors is higher,
being around 9% [20]. In a study conducted in a
representative sample of the city of São Paulo, it was
found that the prevalence varies according to the age
group, peaking in individuals between 30 and 40 years
old. The prevalence in children between 5 and 9 years
old was found to be high (2.9%), suggesting that other
transmission routes, besides parenteral and sexual, are
important in this age group [21].
Whereas the presence of antibodies against the
envelope protein E2 (anti-E2) indicates viral clearance,
the presence of GBV-C RNA in serum or plasma
indicates ongoing GBV-C infection [22]. GBV-C RNA
can be detected by nucleic acid amplification systems
[23-25], and quantification has been accomplished
using branched chain DNA assays [26] and real-time
(Taq Man) polymerase chain reaction (PCR).
GBV-C viremia is associated with a lower mortality
rate among HIV-1 infected patients, slower progression
to AIDS, and longer survival once AIDS has developed
[26-29]. In another study, these effects were found to
be independent of age, HIV-1 load, HCV load, CD
4
+
and CD
8
+ T cell counts, and CC chemokine receptor
5 (CCR5) genotype [30]. It was also observed that
serum levels of interleukin-2 (IL-2), IL-12, IL-4, and
IL-10 remained relatively stable over time in the GBV-
C RNA-positive group, while the GBV-C RNA
negative group had a decrease in IL-2 and IL-12 of
approximately 85% and 83%, respectively, and IL-4
and IL-10 increased by 654 and 395%, respectively,
preserving a TH1 cytokine response [29].
GBV-C virus did not prevent the entry of HIV in
the cell or the depletion of T CD
4
+ cells, but it did have
an inhibitory effect in replication and HIV growth in
cell culture [31]. This effect did not appear to be a
result of cellular toxicity, considering that GBV-C
replication in peripheral-blood mononuclear cells
appeared to be noncytopathic and did not inhibit the
synthesis of cellular proteins [31].
Over the past several years, there has been
substantial controversy over the interactions between
GBV-C and HIV in vivo. A number of studies have
demonstrated a surprising survival benefit among
patients who are coinfected, when compared with those
who are only infected with HIV-1. Other studies,
however, have not shown such effects. The article by
Williams et al. [32] may settle a few aspects of this
controversy, since it clearly demonstrates that five to
six years after HIV-1 seroconversion patients were
more likely to be dead if they were infected only with
HIV-1 than if they were coinfected with both HIV-1
and GBV-C. This significant survival advantage was
not observed during the first 12 to 18 months after
HIV-1 seroconversion. Likewise, the time
dependence could explain the contradictory results
of some studies regarding the observed protective
effects of GBV-C [32].
As further evidence of the protective effect of dual
infections, Williams et al. also found that the course of
HIV-1 disease was adversely affected by the clearance
of GBV-C viremia [32]. The mechanism of this
protective effect remains to be determined and there
are a number of possibilities to explain it.
In addition, some studies suggest that HIV-1
replication is directly reduced by GBV-C. The fact that
both HIV-1 and GBV-C can infect and replicate within
peripheral-blood mononuclear cells suggests that these
two viruses interact either directly or indirectly
throughout the cell cycle. Various stages of the HIV
life cycle may be affected by GBV-C, including
retroviral binding and fusion to target cells through the
high-affinity receptor and several chemokine
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coreceptors, internalization and reverse transcription,
integration into the host-cell genome to create the HIV
provirus, viral transcription, translation and viral
morphogenesis; another possibility is a series of
interactions that involve CCR5.
The level of CCR5 expression is an important factor
for HIV transmission and disease progression [33]. It
was observed that the envelope glycoproteins of GBV-
C, specifically E2, bind to CD
81
  on T lymphocytes.
This interaction induces a dose-dependent secretion
of RANTES, a natural ligand of CCR5, which induces
internalization of CCR5 and down-regulation of CCR5
surface expression, with concomitant intracellular
accumulation of CCR5 proteins on CD
4
+  and CD
8
+  T
lymphocytes of HGV-infected subjects, at a rate of 53
and 36%, respectively. Hence, the internalization of
chemokine receptors is an effective mechanism to block
cellular entry of HIV into the cells [34,35]. However,
it remains unclear why HGV E2 specifically induces
RANTES, but not MIP-1αor MIP-1β, which are
other ligands of CCR5 [36]. On the other hand, it would
be of interest to know whether GBV-C clearance is
associated with HIV-mediated destruction of host cells
necessary for the production of GBV-C, preceding the
loss of CD
4
+  T cells.
There is a long history of interactions between
different viruses; in most cases one virus increases the
pathogenicity of the other. The interaction between
HIV-1 and GBV-C is unusual and curious, and it is
beneficial to patients who are dually infected. It is,
therefore, of great interest to understand the
mechanisms involved in this interaction, because it could
result in progress in our understanding of viral
pathogenesis and in a contribution towards the
development of novel HIV-1 treatment strategies.
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